To include your compound in the COVID-19 Resource Center, submit it here.

The writing has been on the wall for Sanofi’s diabetes, CV business for years

Hudson’s new growth strategy for Sanofi hinges on expanding Dupixent and growing cancer, rare

One hundred days after taking the helm as CEO, Paul Hudson has outlined a plan to get Sanofi to 30% margins by 2022 that hinges largely on the success of Dupixent and five other priority programs, and marks Sanofi’s official exit from its historical strongholds of diabetes and cardiovascular disease.

Hudson, who joined on Sept. 1, unveiled the plan at the pharma’s Capital Markets day on Wednesday, where he said Sanofi (Euronext:SAN; NASDAQ:SNY) was losing money in diabetes and CV diseases and didn’t have first-in-class or best-in-class programs to stem the tide. A restructuring of the pharma’s deal with Regeneron is part of the shift away from CV disease. Hudson was previously CEO of the Novartis Pharmaceutical unit of Novartis AG (NYSE:NVS; SIX:NOVN).

Autoimmune drug Dupixent dupilumab will remain a major focus; beyond that, Sanofi’s priorities will be its fledgling cancer pipeline, rare diseases and vaccines.

Despite the company’s history in diabetes and CV, the change was a long time coming.

The pharma put the disease areas in a separate unit in 2015, and earlier this year culled a dozen programs from its pipeline. What was left largely

Read the full 1850 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE